Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Fresenius

Market Cap 22.31B 25.53B 20.64B 19.26B 36.16B 2,413B 36.42B 245B 95.42B 1,186B 95.86B 93.78B 4,121B P/E 2026 *
11.8x
P/E 2027 * 10.7x
Enterprise Value 32.66B 37.38B 30.21B 28.2B 52.93B 3,532B 53.32B 359B 140B 1,737B 140B 137B 6,033B EV / Sales 2026 *
1.38x
EV / Sales 2027 * 1.28x
Free-Float
72.99%
Yield 2026 *
2.87%
Yield 2027 * 3.12%
Manager TitleAgeSince
Chief Executive Officer 57 2022-09-30
Director of Finance/CFO 46 2022-08-31
Compliance Officer 50 -
Director TitleAgeSince
Director/Board Member 71 2015-05-19
Director/Board Member 65 2016-05-12
Director/Board Member 52 2015-12-31
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 25.59B
+4.52%+2.33%+54.21%+48.44% 125B
+0.14%-3.68%-0.82%+27.59% 83.23B
-0.37%-3.84%+8.18%+40.08% 21.59B
-2.28%-1.02%-13.29%-24.59% 20.42B
+2.83%-1.18%+4.66%+123.43% 14.86B
+1.10%+0.41%-2.19%+3.07% 14.38B
+3.35%+2.45%+57.61%+117.15% 13.35B
+1.35%+1.35%-11.82%-5.04% 12.54B
-0.18%+8.09%-9.85%+88.82% 11.31B
Average -0.41%+0.56%+9.63%+46.55% 35.24B
Weighted average by Cap. +0.79%-0.89%+22.66%+41.37%

Financials

2026 *2027 *
Net sales 23.62B 27.03B 21.85B 20.39B 38.28B 2,555B 38.56B 260B 101B 1,256B 101B 99.29B 4,363B 24.83B 28.42B 22.97B 21.44B 40.25B 2,686B 40.55B 273B 106B 1,321B 107B 104B 4,587B
Net income 1.89B 2.17B 1.75B 1.64B 3.07B 205B 3.09B 20.83B 8.1B 101B 8.14B 7.97B 350B 2.12B 2.43B 1.96B 1.83B 3.44B 230B 3.47B 23.33B 9.08B 113B 9.12B 8.92B 392B
Net Debt 10.35B 11.84B 9.57B 8.93B 16.77B 1,119B 16.9B 114B 44.26B 550B 44.47B 43.5B 1,912B 9.6B 10.99B 8.88B 8.29B 15.56B 1,038B 15.67B 106B 41.05B 510B 41.25B 40.35B 1,773B
Logo Fresenius
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - hospital administration and engineering (59.2%; Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (37.7%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc.; - other (3.1%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
39.61EUR
Average target price
54.79EUR
Spread / Average Target
+38.33%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!